Related Experiment Videos
Trilostane therapy for advanced breast cancer
Cancer Treatment Reports
|April 1, 1985
Summary
Trilostane, a 3 beta D-hydrogenase delta 5-isomerase inhibitor, showed limited efficacy in treating advanced breast cancer. Only one patient responded, with six showing stabilization, indicating it
Area of Science:
- Oncology
- Endocrinology
Background:
- Advanced breast cancer presents a significant therapeutic challenge.
- Hormonal therapies are a cornerstone in managing postmenopausal breast cancer.
Purpose of the Study:
- To evaluate the efficacy of trilostane as a treatment for postmenopausal patients with advanced breast cancer.
Main Methods:
- A clinical study involving 41 postmenopausal patients with advanced breast cancer.
- Patients were treated with trilostane for up to 1 year.
Main Results:
- One patient (approximately 2.4%) demonstrated a response to trilostane.
- Six patients (approximately 14.6%) achieved disease stabilization.
- The majority of patients did not respond to trilostane therapy.
Conclusions:
- Trilostane monotherapy is not an effective treatment for advanced breast cancer.
- Further investigation into combination therapies or alternative agents is warranted.
- Some patients who failed trilostane responded to subsequent endocrine therapies.